News 2020-03-16
Porton Announces Opening of US Technology Center.
Chongqing, China--Porton announced the establishment of Porton U.S.A, LLC, a new subsidiary and Process Innovation Center located in Cranbury, New Jersey (NJ), United States. Deploying state-of-the-art laboratories and some of the industry’s most capable and experienced scientists, Porton’s NJ Center will provide our customers with impactful solutions to complex process challenges, next generation process development, gram to kilogram cGMP syntheses of specialized pharmaceutical intermediates and APIs including highly potent APIs and antibody drug conjugates, etc. Through flexibly structured, yet close-knit collaborations and geographical proximity, Porton’s NJ Center will bring new efficiencies to pharmaceutical development and lifecycle management for our valued global customers.
Others
More
News 2026-08-05
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.

News 2026-07-08
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance